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Essentials
• Research suggests that intensive treatment episodes may increase the risk to develop inhibitors.
• We performed an international nested case-control study with 298 non-severe hemophilia A patients.
• Surgery and a high dose of factor VIII concentrate were associated with increased inhibitor risk.
• Physicians need to review arguments for factor VIII dose and elective surgery extra critically.
Summary. Background: Inhibitor development is a major complication of treatment with factor VIII concentrates in hemophilia. Findings from studies among severe hemophilia A patients suggest that intensive treatment episodes increase the risk of developing inhibitors. Objectives: We set out to assess whether intensive treatment is also associated with an increased risk of inhibitor development among non-severe hemophilia A patients. Patients/Methods: We performed a nested case-control study. A total of 75 inhibitor patients (cases) and 223 control patients were selected from 2709 non-severe hemophilia A patients (FVIII:C, 2-40%) of the INSIGHT cohort study. Cases and controls were matched for date of birth and cumulative number of exposure days (EDs) to FVIII concentrates. Conditional logistic regression was used to calculate both unadjusted and adjusted odds ratios (aOR); the latter were adjusted for a priori specified confounders. Results: Peak treatment of 5 or 10 consecutive EDs did not increase inhibitor risk (aOR, 1.0; 95% confidence interval (CI), 0.4-2.5; and aOR, 1.8; CI, 0.6-5.5, respectively). Both surgical intervention (aOR, 4.2; CI, 1.7-10.3) and a high mean dose (> 45 IU kg À1 /ED) of FVIII concentrate (aOR, 7.5;
CI, 1.6-35.6) were associated with an increased inhibitor risk. Conclusions: Our findings suggest that highdose FVIII treatment and surgery increase the risk of inhibitor development in non-severe hemophilia A. Together with the notion that non-severe hemophilia A patients are at a lifelong risk of inhibitor development, we suggest that in the future physicians will review the arguments for the FVIII dose and elective surgery extra critically.
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Introduction
Hemophilia A is an X-linked hereditary bleeding disorder, caused by a decrease in the level of clotting factor VIII (FVIII). In patients with hemophilia A bleeding is treated with FVIII concentrates. The standard of care in severe hemophilia A patients is prophylactic treatment with FVIII concentrates one to three times a week. This contrasts with non-severe hemophilia A patients, who only need treatment with FVIII concentrates in the case of (severe) trauma or surgery. A major complication of treatment with FVIII concentrates is the development of inhibiting anti-FVIII antibodies (inhibitors).
Inhibitors occur in approximately 25-30% of patients with severe hemophilia A and in 13% of non-severe hemophilia A patients [1, 2] , causing increased morbidity and mortality [3, 4] .
The etiology of inhibitor development is multifactorial and both genetic and treatment-related risk factors have been described.
Until now, the genetic risk factor most strongly associated with inhibitors is the F8 genotype [5] [6] [7] . Other genetic risk factors are polymorphisms in immune regulatory genes [8, 9] , the HLA genotype [10, 11] , family history of inhibitor development [12] and ethnicity [12, 13] .
Exposure to FVIII concentrate is a prerequisite for an inhibitor to arise. The risk of inhibitor development greatly depends on the cumulative number of exposure days to FVIII concentrate (EDs). In severe hemophilia A patients, inhibitors predominantly occur early in treatment (during the first 50 EDs). We demonstrated that in non-severe hemophilia A patients the cumulative incidence of inhibitors continues to rise after 50 EDs, up to an incidence of 13.3% at 100 EDs. Therefore, when studying the association between any risk factor and inhibitor development it is essential to take the number of cumulative exposure days into account, because this is a strong confounder.
Furthermore, the risk of inhibitor development may be affected by the conditions associated with treatment at a certain exposure day, such as reason for treatment, intensity of treatment and the dose of FVIII administered [14] [15] [16] [17] . Some of these conditions may influence the activation state of the immune system, as suggested by the immunological 'danger theory' of P. Matzinger. The 'danger theory' states that the driving force behind activation of the immune system is the need to detect and protect against danger. The immune system receives positive and negative signals from various bodily tissues to accomplish this [18] . According to this theory, administration of FVIII in the presence of 'danger signals' confers an increased risk of inhibitor development. These danger signals include cytokine release and co-stimulatory signaling and may arise from inflammation or tissue damage. Therefore, surgery has been widely studied as a risk factor for inhibitor development [16, 17, [19] [20] [21] .
In non-severe hemophilia A patients only some of these treatment-related risk factors have been studied and studies in non-severe hemophilia A are often small compared with studies in severe hemophilia A [22, 23] . Identifying clinical situations that elicit inhibitor development in this specific patient group is important, as this enables the design of preventive strategies. We analyzed the association of different treatment-related risk factors with inhibitor development in non-severe hemophilia A.
Methods

Patients
We conducted a case-control study, nested in a cohort of 2709 consecutive non-severe hemophilia A patients (FVIII:C 2-40%) who received at least one exposure to FVIII concentrate in 33 European centers and one Australian center between 1 January 1980 and 1 January 2011. The institutional review boards of all participating centers approved the study. All patients from the source population were followed-up from birth until death, emigration, loss to follow-up or the end of the study. For further information we refer to previously published papers of the INSIGHT cohort [2, [24] [25] [26] .
The primary outcome was clinically relevant inhibitor development, defined as having at least two consecutive positive Bethesda inhibitor assay titers of ≥ 1.0 Bethesda Units (BU) per mL. Patients with inhibitor titers between 0.6 and 1.0 BU mL À1 had to fulfill one of the following two criteria to be classified as having a clinically relevant inhibitor: (i) a decrease in endogenous FVIII plasma level to at least 50% of the baseline level or (ii) a reduced half-life of less than 6 h after FVIII concentrate administration. Patients who were not tested for inhibitors during the followup period and who had no clinical features of inhibitor development (e.g. increased bleeding tendency) were classified as negative for inhibitors. All nonsevere hemophilia A patients who developed a clinically relevant inhibitor during follow-up were identified as case patients. All non-severe hemophilia A patients from our cohort who did not develop an inhibitor during follow-up were identified as eligible controls.
A maximum of four control patients were matched to each case by date of birth, cumulative number of EDs to FVIII concentrates and center or country. The definitions of the criteria for matching a control to a specific case were: (i) at least the same number of cumulative exposure days (or more) and (ii) date of birth within AE 10 years of the date of birth of the case. Controls were selected from the same treatment center as the case; if there were no eligible controls in the same treatment center, controls were selected from the same country. Please see Fig. 1 for a selection of cases and controls. Cases that received > 75 exposure days (because detailed information on all EDs was not available) and their matched controls or cases whose total number of exposure days was not available, were excluded.
Data collection
Clinical characteristics were collected for the complete INSIGHT cohort, including FVIII:C baseline level, total number of EDs, F8 genotype, ethnicity, family history of hemophilia A and inhibitor development. The F8 genotype was categorized into three categories (low risk of mutation, high risk of mutation, risk of mutation unknown) based on the HAMSTERS and CHAMP databases [27, 28] .
For the cases and controls, detailed clinical data on every FVIII exposure were collected until inhibitor development in cases and up to the same number of exposure days in the matched controls, including calendar date of every exposure day, type, dose and mode of administration of FVIII product, and mode and reason for treatment (including types and locations of bleeding and types of surgical intervention).
All data collected were repeatedly checked for irregularities and completeness by two study coordinators.
Determinants
In patients with non-severe hemophilia A it is extremely challenging to dissect the reason for treatment (surgery, trauma or a spontaneous bleed) from the intensity of treatment. When we compare differences in reasons for treatment (e.g. surgery vs. a spontaneous bleed) in most cases automatically there will also be a difference in the intensity of treatment. In this example, surgery is associated with a peak treatment moment and a higher dose compared with a spontaneous bleed.
To be able to investigate the effect of treatment intensity on inhibitor development in non-severe hemophilia A patients, we separately studied the following three parameters: peak treatment moments (classified into three different categories), the dose of FVIII concentrate (in IU per kg bodyweight per ED) and reason for treatment. The reason for treatment was classified as: surgical intervention, spontaneous bleeding episode, bleeding as a result of trauma and 'other reason' (e.g. prophylaxis, testing and research). We appraised the intensity of treatment with FVIII concentrates by investigating peak treatment moments and the dose of FVIII concentrates that was administered.
We defined three categories of peak treatment moments: (i) at least three consecutive EDs to FVIII concentrate within a maximum of five calendar days, (ii) at least five consecutive EDs within a maximum of 5-10 calendar days and (iii) at least 10 consecutive EDs within a maximum of 14 calendar days.
Missing data
The missing calendar dates of exposure days were unconditionally imputed with the middle value between the dates before and after the missing dates (< 0.5%).
If the reason for treatment was missing for an exposure day and one calendar day before or after an ED with known reason for treatment was present, the missing value was replaced with the reason for treatment of that ED. In all other cases missing values were unconditionally imputed with 'trauma' as the reason for treatment, because the assumption was made that this is the most probable reason for treatment in this patient group when the reason for treatment was missing.
Missing values of the FVIII dose were replaced with the value of the average dose that was administrated for that specific treatment indication in that specific treatment center.
Data analyses
We used conditional logistic regression methods as these account for the matching of cases and controls and the analysis is performed using the matched groups (i.e. one case and one to four controls).
Crude as well as adjusted odds ratios (ORs) are presented. We adjusted for determinants that could have possibly confounded the associations studied, independent of their statistical significance in univariate analyses. The predefined confounders that were adjusted for in the analysis are: endogenous FVIII:C baseline level, F8 mutation, ethnicity, family history of inhibitors, age at first ED and last ED (of follow-up), calendar date and product type.
Results
Patient characteristics
In total, 7832 exposure days of 298 patients were included in this case-control study. Figure 1 shows an overview of the patients' inclusion.
The median age at first exposure of all patients was 23 years (interquartile range [IQR] 5-44) and the median baseline (endogenous) FVIII level was 8 IU dL À1 (IQR, [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] . The 75 cases (inhibitor patients) developed an inhibitor after a median of 25 EDs (IQR, 12-40) . The median titer of the first positive inhibitor test was 2 BU mL À1 (IQR, 1-7) and the median inhibitor peak titer was 7 BU mL À1 (IQR, 2-26). In total, 39 (52%) cases had a high titer inhibitor. Baseline characteristics for cases and controls are shown in Table 1 .
Association between intensity of treatment and inhibitor development
In Table 2 all crude and adjusted odds ratios for inhibitor development are displayed.
Reason for first treatment
Most patients received their first treatment for a bleed due to trauma (n = 125, 42%). Surgical intervention as a reason for first treatment was associated with an increased risk of inhibitor development compared with a spontaneous bleed with an adjusted odds ratio (OR) of 3.9 (95% confidence interval [CI], 1.4-10.7). For the category 'other reasons' the adjusted OR was also increased when compared with treatment for spontaneous bleeds or trauma; however, this was not statistically © 2017 International Society on Thrombosis and Haemostasis significant (OR 3.7, CI 0.7-20.4). In total, 11 patients were included in the category 'other reason' at first treatment; reasons in this category included testing, research (first dose part of a clinical trial) and prophylaxis. Of the four patients that had developed an inhibitor, two patients had a high-risk mutation (Arg593Cys).
Peak treatment at first treatment
A peak treatment of 5 EDs or 10 EDs at first treatment did not increase the risk of inhibitor development (adjusted OR, 1.0; CI, 0.4-2.5 and adjusted OR, 1.8; CI, 0.6-5.5, respectively). 
Reason for treatment
Surgery: during complete follow-up and in the last 6 months If a patient had ever undergone a surgical intervention the adjusted risk of inhibitor development was 4.2 times higher (CI, 1.7-10.3) compared with patients who had never undergone surgery. Secondly, surgery in the last 6 months before the end of follow-up was also associated with an increased risk of inhibitor development (adjusted OR, 3.8; CI, 1.6-9).
Peak treatment Peak treatment with 5 or 10 EDs was not associated with an increased risk of inhibitor development in comparison with the group that never experienced a peak treatment (adjusted OR, 1.6; CI, 0.3-8.6 and 3.8; CI, 0.6-23.8, respectively).
Dose of FVIII concentrate
Mean dose of all exposure days and mean dose of the last 10 EDs Compared with the lowest mean dose of 0-25 IU/kg, the risk of inhibitor development was significantly higher when patients had received a mean dose of >45 IU/kg (adjusted OR, 7.5; CI, 1.6-35.6). The association between high mean FVIII dose and inhibitor development was more prominent for the last 10 EDs (adjusted OR, 11.9; CI, 2.4-59.5).
Discussion
In this nested case-control study we investigated the association between the intensity of treatment and inhibitor development among 298 non-severe hemophilia A patients. The risk of inhibitor development was increased for patients who were treated with high FVIII doses (> 45 IU/kg per dose). Surgical interventions were also associated with an increased risk of inhibitor development.
The strong association between the treatment with a high dose of FVIII concentrate and inhibitor development has been observed in previous studies on risk factors for inhibitor development in severe hemophilia A patients. In the current literature, the emphasis often is placed on surgery and peak treatment moments as being important clinical risk factors. The results from this study stress the OR, odds ratio; aOR, adjusted odds ratio; CI, confidence interval; ED, exposure day. *Adjusted for confounders: endogenous FVIII level, ethnicity, F8 genotype, positive family history of inhibitors, product type (rec/pd), age at first ED and at last ED, calendar date. †Forty nine patients were censored from analysis because of missing data on dose. ‡No surgery vs. minor, intermediate and major surgery. §Fifty four patients were censored from analysis because of missing data on dose. ¶ ¶Forty six patients were censored from analysis due to missing data on dose.
importance of the dose of FVIII concentrate. Especially in non-severe hemophilia A patients, who have a lifelong risk of inhibitor development [2] , with every new exposure day the treating physician should be critically considering which dose of FVIII concentrate is needed for a specific patient with a specific condition. In our study we did not find an increased risk of inhibitor development after peak treatment, contrary to some studies in severe hemophilia A patients [16, 21] . This could be caused by a lack of contrast for the peak treatment variable in our data, because the majority of the exposures in non-severe hemophilia A patients are a peak treatment of 3 or more exposure days. In severe hemophilia A the majority of patients are treated with prophylaxis and therefore regularly receive one exposure day at a time. Comparing prophylactic treatment with peak treatments results in a larger difference, and therefore a difference can become more apparent in the data of severe hemophilia A patients.
Because of the design of this study, a nested case-control study for which cases and controls were selected from a large unselected cohort of non-severe hemophilia A patients, selection bias was reduced. By selection of 298 patients for this case-control study out of more than 2700 patients in the INSIGHT cohort study, our study has become the largest case-control study on risk factors for inhibitor development in non-severe hemophilia A patients. Through the matching of cases and controls for the strongest confounder (i.e. the number of exposure days) and using a conditional logistic regression model, we compared cases with controls with the same number of exposure days. Detailed clinical data on every exposure day were available. This enabled us to adjust associations for potential treatment-related confounders.
'Mean' dose was the determinant most strongly associated with inhibitor development in this study, especially the mean dose during the last 10 EDs before inhibitor development (or end of follow-up for matched controls). Although we corrected for age at first and at last ED, in the multivariate analyses we did not correct for surgery. The dose used and the reason for treatment (e.g. surgery) are two strongly correlated variables and therefore should not be adjusted for each other because this may lead to over-adjusting and thereby concealing the true effect.
The association between a high FVIII dose and inhibitor development could also be explained by reversed causality: the use of a high FVIII dose may be because of developing inhibitory antibodies (which render the FVIII treatment ineffective) instead of causing it [16] . However, when considering FVIII dose only in the first 10 exposure days we also found a strong association between high FVII dose and inhibitor development and at such an early moment in the treatment it is unlikely that antibodies have already occurred.
We acknowledge the limitations of retrospective data collection. Because we needed to go back more than 20 years to collect the data for some patients, we were confronted with variety in the quality of medical record keeping over the years. However, especially in a patient group where it is very difficult, if not impossible, to collect sufficient patient numbers to perform prospective studies, we need to value and use the data that we can collect retrospectively.
To establish whether and how treatment strategies influence the risk of inhibitors, the determinant 'intensity of treatment' should be disaggregated into the reason for treatment, peak treatment moments and FVIII dose. However, because these determinants are extremely interconnected it is highly unlikely that they can ever be assessed completely independent of each other. Therefore, with the interpretation of the results of our analysis one should keep in mind that (for example) the association between high FVIII dose and inhibitor development could still be affected by how the reason for treatment and peak treatment moments are distributed over the different groups under comparison.
In conclusion, our findings suggest that high-dose FVIII treatment and surgery increase the odds ratio for inhibitor development in non-severe hemophilia A (7.5 and 4.2, respectively). Together with the notion that nonsevere hemophilia A patients are at a lifelong risk of inhibitor development, we suggest that in the future physicians will review the arguments for the FVIII dose and elective surgery extra critically [29] . Addendum A. S. van Velzen collected, interpreted, cleaned, checked, and analyzed the data, and wrote the manuscript. C. L. Eckhardt collected and interpreted the data and reviewed, edited, and approved the final version of the manuscript. J. G. van der Bom designed the study, supervised the interpretation and statistical analysis of the data, and reviewed and approved the final version of the manuscript. K. Fijnvandraat designed and supervised the study, wrote the protocol, and wrote and edited the manuscript. The other authors collected the data or supervised data collection, and reviewed and approved the final version of the manuscript. manuscript. The authors would like to thank S. Gouw and S. le Cessie for help and advice with statistical analyses and interpretation of the data. A complete list of the members of the INSIGHT study group appears in the Appendix.
Disclosure of Conflict of Interests
C. Escuriola-Ettingshausen reports grants, personal fees, and travel support from Baxalta/Shire, Bayer, CSL Behring, and Octapharma; grants and personal fees from Biotest; and personal fees and travel support from Grifols, LFB, and Novo Nordisk, outside the submitted work. A. S. van Velzen has given lectures at educational symposiums organised by Novo Nordisk, Baxter, and Pfizer and has received unrestricted research funding from CSL Behring. C. L. Eckhardt has given lectures at educational symposiums organised by Novo Nordisk and Baxter. F. W. G. Leebeek received unrestricted grants from CSL Behring and Baxter for research activities unrelated to this manuscript and is a consultant for UniQure (not related to this study). C. Male has received speakers' honoraria and travel support from Baxalta, Baxter, Bayer, Biotest, CSL Behring, Novo Nordisk, and Pfizer, and an unrestricted grant from CSL Behring. J. G. van der Bom has received payment for consultancy meetings with Bayer and Wyeth; has received grants from Bayer Schering Pharma, Baxter; CSL Behring, Novo Nordisk, and Wyeth; and has received payment for lectures from Bayer. K. Fijnvandraat is a member of the European Hemophilia Treatment and Standardisation Board sponsored by Baxter; has received unrestricted research grants from CSL Behring, Pfizer, and Bayer; and has given lectures at educational symposiums organised by Pfizer and Bayer. J. Astermark grants from reports Baxalta, Bayer, and SOBI/Biogen, outside the submitted work. The other authors state that they have no conflict of interest.
